Fluorescence anisotropy of membrane fluidity probes in human erythrocytes incubated with anthracyclines and glutaraldehyde

Bioelectrochemistry

Volumn 74, Issue 2, 2009, Pages 236-239

  Marczak, Agnieszka ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Daunorubicin; Erythrocytes; Fluidity; Glutaraldehyde; Idarubicin

Indexed keywords

ALDEHYDES; CYTOLOGY; FLUIDITY; LIPID BILAYERS;

ANTHRACYCLINES; DAUNORUBICIN; ERYTHROCYTES; FLUORESCENCE ANISOTROPIES; GLUTARALDEHYDE; HUMAN ERYTHROCYTES; HYDROPHOBIC REGIONS; IDARUBICIN; MEMBRANE FLUIDITIES; PLASMA MEMBRANES;

CELL MEMBRANES;

1,6 DIPHENYL 1,3,5 HEXATRIENE; 8 ANILINO 1 NAPHTHALENESULFONIC ACID; DAUNORUBICIN; FLUORESCENT DYE; GLUTARALDEHYDE; IDARUBICIN; STEARIC ACID;

ANISOTROPY; ARTICLE; CELL MEMBRANE; ERYTHROCYTE; FLUORESCENCE SPECTROSCOPY; HUMAN; HYDROPHOBICITY; LIPID BILAYER; MEMBRANE FLUIDITY;

ANTHRACYCLINES; DAUNORUBICIN; ERYTHROCYTES; FLUORESCENCE POLARIZATION; GLUTARAL; HUMANS; IDARUBICIN; LIPID BILAYERS; MEMBRANE FLUIDITY; MOLECULAR PROBE TECHNIQUES;

EID: 58349108511     PISSN: 15675394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bioelechem.2008.11.004     Document Type: Article

References (38)

1. Marczak A., Wrzesień-Kuś A., Krykowski E., Robak T., and Jóźwiak Z. The interaction of daunorubicin and mitoxantrone with red blood cells of acute myeloid leukemia patients. Cell. Mol. Biol. Lett. 8 (2003) 885-890
2. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004) 185-229
3. Tallman M.S., Gilliland D.G., and Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 106 (2005) 1154-1163
4. Marczak A., Kowalczyk A., Wrzesień-Kuś A., Robak T., and Jóźwiak Z. The interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukemia patients. Cell Biol. Int. 30 (2006) 127-132
5. Lotfi K., Zackrisson A.L., and Peterson C. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. Cancer Lett. 178 (2002) 141-149
6. Masquelier M., Zhou Q.F., Gruber A., and Vitols S. Relationship between daunorubicin concentration and apoptosis induction in leukemic cells. Biochem. Pharmacol. 67 (2004) 1047-1456
7. Dragojew S., Marczak A., Maszewski J., Ilnicki K., and Jóźwiak Z. Induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell. Mol. Biol. Lett. 13 (2008) 182-194
8. Klimtova I., Simunek M., Mazurova Y., Hrdina Y., Gersl V., and Adamcova M. Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits. Human Exp. Toxicol. 21 (2002) 649-657
9. Wildiers H., Highley M.S., de Bruijn E.A., and van Oosterom A.T. Pharmacology of anticancer drugs in the elderly population. Clin. Pharmacokinet. 42 (2003) 1213-1242
10. Levitt G.A., Dorup I., Sorensen K., and Sullivan I. Does anthracycline administration by infusion in children affect late cardiotoxicity?. Br. J. Haematol. 124 (2004) 463-468
11. Simunek T., Klimtova I., Kaplanova J., Sterba M., Mazurova Y., Adamcova M., Hrdina R., Gersl V., and Ponka P. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol. Res. 51 (2005) 223-231
12. Cersosimo R.J. Idarubicin: an anthracycline antineoplastic agent. Clin. Pharm. 11 (1992) 152-167
13. Schrijvers D. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin. Pharmacokinet. 42 (2003) 779-791
14. Gothoskar A.V. Resealed erythrocytes: a review. Pharm. Technol. (2004) 140-158
15. Millan C.G., Marinero M.L., Castaneda A.Z., and Lanao J.M. Drug, enzyme and peptide delivery using erythrocytes as carriers. J. Control. Release 95 (2004) 27-49
16. Jordan J.A., Murciano J.C., Lotero A., Herraez A., and Diez J.C. In vitro properties and organ uptake of rat band 3 cross-linked erythrocytes. Biochimie 79 (1997) 53-61
17. Fan H., and Dash A.K. Effect of cross-linking on the in vitro release kinetics of doxorubicin from gelatin implants. Int. J. Pharm. 213 (2001) 110-116
18. Ataullakhanov F.I., Kulikova E.V., and Vitvitsky V.M. Reversible binding of anthracyclines treated with glutaraldehyde. Biotechnol. Appl. Biochem. 24 (1996) 241-244
19. Szwarocka A., and Jóźwiak Z. The effect of daunorubicin and glutaraldehyde treatment on the structure of erythrocyte membrane. Int. J. Pharm. 181 (1999) 117-123
20. Szwarocka A., Kowalczyk A., Łubgan D., and Jóźwiak Z. The combined effect of IDA and glutaraldehyde on the properties of human erythrocytes. Int. J. Pharm. 220 (2001) 43-51
21. Marczak A., Walczak M., and Jóźwiak Z. The combined effect of IDA and glutaraldehyde on the erythrocyte membrane proteins. Int. J. Pharm. 335 (2007) 154-162
22. Marczak A., and Jóźwiak Z. The interaction of DNR and glutaraldehyde with cell membrane proteins leads to morphological changes in erythrocytes. Cancer Lett. 260 (2008) 118-126
23. Curatola G., and Lenaz G. Role of plasma membrane fluidity in the regulation of cellular activities. In: Akkas N. (Ed). Biomechanics of Cell Division (1987), Plenum, New York 33-77
24. Van der Meer B.W. Subcellular biochemistry. In: Hilderson H.J., and Harris J.R. (Eds). Fluorescence Studies on Biological Membranes vol. 13 (1988), Plenum Press, New York 1-53
25. Shinitzky M., and Barenholz Y. Fluidity parameters of lipid regions determined by fluorescence polarization. Biochim. Biophys. Acta 515 (1978) 367-394
26. Kuhry J.G., Duportail G., Bronner C., and Laustriat G. TMA-DPH: a suitable fluorescence polarization probe for specific plasma membrane fluidity studies in intact living cells. Cell Biophys. 5 (1983) 129-140
27. Prendergast F.G., Haugland R.P., and Gallahan P.J. 1-[4-(trimethylammonium) phenyl]-6-phenyl-1,3,5-hexatriene: synthesis, fluorescence properties and use as a fluorescence probe of lipid bilayers. Biochemistry 20 (1981) 7333-7338
28. Ma J.Y.C., Ma J.K.H., and Weber K.C. Fluorescence studies of the binding of amphiphilic amines with phospholipids. J. Lipid Res. 26 (1985) 1985735-1985744
29. Masumoto N., Tasaka K., Mizuki J., Tahara M., Miyake A., and Tanizawa O. Dynamics of exocytosis and recycling in single pituitary gonadotropes. Biochem. Biophys. Res. Commun. 197 (1993) 207-213
30. Zgirski A., and Gondko R. Biochemical evaluations (1998), PWN, Warszawa
31. Szwarocka A., Fiet I., and Jóźwiak Z. Idarubicin - induced changes in human erythrocyte membranes. Biomed. Lett. 56 (1997) 81-89
32. Fung L.W. Analysis of spin-labeled erythrocyte membranes. Ann. N.Y. Acad. Sci. 414 (1983) 162-168
33. Butterfield D.A., and Palmieri D.A. Spin-labeling studies of the interaction of 9-amino-1,2,3,4-tetrahydroacridine (THA), a proposed drug for the treatment of Alzheimer's disease, with erythrocyte membranes. Biochem. Arch. 6 (1990) 129-140
34. Goebel M. Oral idarubicin - an anthracycline derivative with unique properties. Ann. Hematol. 66 (1993) 33-43
35. Tidefelt U., Sundman-Engberg B., and Paul C. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukaemia. Leuk. Res. 18 (1994) 293-297
36. Lejeune A., Moorjani M., Gicquaud C., Lacroix J., Poyet P., and Gaudreault R.C. Nanoerythrosome, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin. Anticancer Res. 14 (1994) 915-920
37. Gerweck L. The pH difference between tumor and normal tissue offers a tumor specific target for the treatment of cancer. Drug Resist. Updat. 3 (2000) 49-50
38. Evelhoch J.L. pH and therapy of human cancers. Novartis Found. Symp. 240 (2001) 68-80